The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | Lessening the economic burden of treating CLL
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses the economic burden of treating chronic lymphocytic leukemia (CLL). A solution Dr Eichhorst proposes is raising the price of treatment in the beginning, but ensuring that this treatment eradicates the disease. Consequently the patient does not have to pay for continuous treatment. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
